Device Trial Radar · NCT06627673
MultiCenter IDE Study of the PEEK-OPTIMA™ Femoral Component vs a CoCr Alloy TKA Femoral Component of Similar Design
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Jan 1, 2029
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- Maxx Orthopedics IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this investigational device exemption (IDE) study is to monitor the performance (safety and efficacy) of the Maxx Orthopedics, Freedom Total Knee® System, with a femoral component of similar design, manufactured from polyether-ether-ketone (PEEK).
Conditions
- Knee Osteoarthritis
Interventions
Total Knee ArthroplastyDevice
Primary Total Knee Arthroplasty with a PEEK femoral component
Primary outcomes
What the sponsor says the trial is designed to measure.
- Original Knee Society ScoreTime frame: 24 months post-treatment.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Ascentis
Leawood, Kansas · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.